Department of Translational Oncology, St. Marianna University Graduate School of Medicine, Kawasaki, Japan. Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.
Institute of Advanced Medical Science, St. Marianna University Graduate School of Medicine, Kawasaki, Japan.
Cancer Res. 2015 Apr 1;75(7):1311-21. doi: 10.1158/0008-5472.CAN-14-2796. Epub 2015 Jan 29.
Stable retention of BRCA1/BARD1 complexes at sites of DNA damage is required for the proper response to DNA double-strand breaks (DSB). Here, we demonstrate that the BRCT domain of BARD1 is crucial for its retention through interaction with HP1. In response to DNA damage, BARD1 interacts with Lys9-dimethylated histone H3 (H3K9me2) in an ATM-dependent but RNF168-independent manner. This interaction is mediated primarily by HP1γ. A conserved HP1-binding motif in the BARD1 BRCT domain directly interacted with the chromoshadow domain of HP1 in vitro. Mutations in this motif (or simultaneous depletion of all three HP1 isoforms) disrupted retention of BARD1, BRCA1, and CtIP at DSB sites and allowed ectopic accumulation of RIF1, an effector of nonhomologous end-joining, at damaged loci in S-phase. UNC0638, a small-molecule inhibitor of histone lysine methyltransferase (HKMT), abolished retention and cooperated with the PARP inhibitor olaparib to block cancer cell growth. Taken together, our findings show how BARD1 promotes retention of the BRCA1/BARD1 complex at damaged DNA sites and suggest the use of HKMT inhibitors to leverage the application of PARP inhibitors to treat breast cancer.
BRCA1/BARD1 复合物在 DNA 损伤部位的稳定保留对于正确应对 DNA 双链断裂(DSB)是必需的。在这里,我们证明 BARD1 的 BRCT 结构域对于其通过与 HP1 的相互作用而保留是至关重要的。在 DNA 损伤反应中,BARD1 以 ATM 依赖性但 RNF168 非依赖性的方式与 Lys9 二甲基化组蛋白 H3(H3K9me2)相互作用。这种相互作用主要由 HP1γ介导。BARD1 BRCT 结构域中的一个保守的 HP1 结合基序在体外直接与 HP1 的染色质阴影结构域相互作用。该基序中的突变(或同时耗尽所有三种 HP1 同工型)破坏了 BARD1、BRCA1 和 CtIP 在 DSB 部位的保留,并允许非同源末端连接效应因子 RIF1 在 S 期受损基因座中外位积累。UNC0638 是组蛋白赖氨酸甲基转移酶(HKMT)的小分子抑制剂,可破坏保留并与 PARP 抑制剂奥拉帕利协同作用,阻止癌细胞生长。总之,我们的研究结果表明 BARD1 如何促进 BRCA1/BARD1 复合物在受损 DNA 部位的保留,并提示使用 HKMT 抑制剂来利用 PARP 抑制剂治疗乳腺癌。